Blog
RSS FeedPosted by Michael Wonder on 16 Dec 2015
NICE says yes to dry eye disease treatment in final guidance
16 December 2015 - NICE has published final guidance recommending cyclosporin (Ikervis, Santen Pharmaceutical) for treating severe keratitis in adults with ...
Posted by Michael Wonder on 14 Dec 2015
NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information
11 December 2015 - The draft recommendations say that olaparib should be available for people only if they have had ...
Posted by Michael Wonder on 13 Dec 2015
NICE publishes draft guidance on two prostate cancer treatments
11 December 2015 - NICE has issued draft guidance for enzalutamide and abiraterone acetate as treatment options for prostate cancer. ...
Posted by Michael Wonder on 13 Dec 2015
NICE gives green light to innovative drug for common heart condition
11 December 2015 - In draft guidance published today for consultation, NICE has provisionally recommended novel heart failure combination product sacubitril ...
Posted by Michael Wonder on 05 Dec 2015
Benefits of new drug to treat rare inherited bone disorder too uncertain to justify its high cost says NICE in draft guidance
3 December 2015 - NICE has today published draft guidance as part of its highly specialised technologies programme that does not ...
Posted by Michael Wonder on 03 Dec 2015
Alexion's $550,000 bone drug too expensive for Britain
2 December 2015 - A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals ALXN.O that costs more ...
Posted by Michael Wonder on 03 Dec 2015
NICE turns down Alexion's £366K-a-year bone disease drug
3 December 2015 - NHS cost regulators are planning to reject Alexion’s therapy for an ultra-rare bone disorder called paediatric-onset hypophosphatasia, ...
Posted by Michael Wonder on 03 Dec 2015
NICE u-turn on Novartis' multiple myeloma drug
3 December 2015 - The National Institute for Health and Care Excellence is now recommending Novartis’ Farydak as a third-line treatment ...
Posted by Michael Wonder on 25 Nov 2015
NICE publishes final drug recommendations for the treatment of four separate medical conditions
25 November 2015 - Each piece of guidance looked at the cost-effectiveness of a particular drug to treat a specific medical ...
Posted by Michael Wonder on 25 Nov 2015
NICE consults on ovarian cancer treatments draft guidance
24 November 2015 - The draft guidance gives provisional recommendations on whether paclitaxel, pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, trabectedin and ...
Posted by Michael Wonder on 25 Nov 2015
NICE draft guidance recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement
23 November 2015 - In final draft guidance as part of its Highly Specialised Technologies Programme, NICE has provisionally recommended Elosulfase ...
Posted by Michael Wonder on 20 Nov 2015
Consultation now open on plans to reform Cancer Drugs Fund
19 November 2015 - NHS England and NICE have begun a consultation on a new Cancer Drugs Fund. ...
Posted by Michael Wonder on 19 Nov 2015
NICE, NHS England consult on Cancer Drugs Fund revamp
19 November 2015 - Long-awaited plans for the future of England’s Cancer Drugs Fund have now been unveiled, with proposals centred ...
Posted by Michael Wonder on 19 Nov 2015
NICE OK's restricted use of Bayer's prostate cancer drug Xofigo
19 November 2015 - NICE will this morning issue a Final Appraisal Determination recommending the use of Bayer’s Xofigo on the ...
Posted by Michael Wonder on 19 Nov 2015
NICE issues draft guidance on evolocumab for lipid disorder
18 November 2015 - NICE has published draft guidance not recommending evolocumab (Repatha, Amgen) as an option for people with high ...